Mechanism of Manganese Dioxide Nanomaterials Activating Stem-like CD8⁺ T Cells via Regulating Extracellular K⁺ Concentration

Technical Summary: Mechanism of Manganese Dioxide Nanomaterials Activating Stem-like CD8⁺ T Cells via Regulating Extracellular K⁺ Concentration

Problem Statement
CD8⁺ T cells are the core effector cells in anti-tumor immunity, yet their function is often compromised within the tumor microenvironment (TME). A critical factor contributing to this dysfunction is the abnormally elevated extracellular potassium (K⁺) concentration resulting from tumor cell necrosis. High-K⁺ stress induces metabolic disorders, including glucose metabolism suppression and essential amino acid deficiency, triggering autophagy in CD8⁺ T cells. Furthermore, this stress reshapes histone epigenetic modifications, leading to the aberrant upregulation of the transcription factor TCF7 (TCF-1). While TCF7 is a marker for stem-like properties, its dysregulated overexpression under high-K⁺ conditions sustains a dysfunctional, stem-like state that lacks cytotoxicity and proliferative capacity, ultimately facilitating tumor immune escape. Current immunotherapies face limitations due to the complexity of the TME and treatment resistance, necessitating novel strategies to regulate the ionic microenvironment and restore T cell function.

Methodology
The study employed a multi-level approach combining material synthesis, in vitro cell assays, metabolomics, and in vivo animal models:

• Material Synthesis and Characterization: $\alpha$-MnO₂ nanorods were synthesized via a hydrothermal method using potassium permanganate and manganese sulfate. The materials were characterized using X-ray diffraction (XRD), Transmission Electron Microscopy (TEM), High-Resolution TEM (HRTEM), and Selected Area Electron Diffraction (SAED) to confirm crystal structure and morphology. Energy-dispersive X-ray spectroscopy (EDX) was used to verify K⁺ adsorption.
• In Vitro Cell Models: Human leukemia T lymphocytes (CD8⁺) and mouse CD8⁺ T cells were cultured under four conditions: Control, High-K⁺ ($\alpha$-K), MnO₂ alone ($\alpha$-MnO₂), and MnO₂ combined with High-K⁺ (K-$\alpha$-MnO₂). Interventions lasted 10 days.
• Functional and Metabolic Assays:
  • Cell Viability: Assessed via CCK-8 assays and microscopic observation of autophagy.
  • Metabolomics: LC-MS/MS was utilized to analyze intracellular amino acid profiles, focusing on nitrogen metabolism and essential amino acids.
  • Protein Expression: Western blotting quantified TCF7 protein levels, normalized to GAPDH.
  • Stemness Phenotype: Multiplex immunofluorescence and flow cytometry were used to quantify CD8⁺TCF-7⁺ stem-like T cell populations.
• In Vivo Models: A B16F10 melanoma mouse model (C57BL/6J) was established. Mice were treated with PBS, High-K⁺, MnO₂, or K-MnO₂ for 14 days. Tumor growth, survival rates, and tissue histology (immunofluorescence) were monitored.

Key Results

• Material Properties: The synthesized $\alpha$-MnO₂ nanorods (50–150 nm length, ~10 nm diameter) exhibited a pure tetragonal phase. EDX analysis confirmed the successful immobilization of K⁺ onto the MnO₂ surface, with potassium comprising 3.29% by weight.
• Reversal of High-K⁺ Toxicity: High-K⁺ stress significantly reduced CD8⁺ T cell viability and induced autophagy. The addition of MnO₂ (K-$\alpha$-MnO₂ group) effectively reversed these detrimental effects, restoring cell viability and reducing autophagic cell proportions.
• Metabolic Remodeling: Metabolomic analysis revealed that High-K⁺ stress depleted essential amino acids. MnO₂ intervention reprogrammed the metabolic phenotype, significantly upregulating immune-related amino acids (L-arginine, L-citrulline, L-histidine, L-valine) and downregulating structural synthesis amino acids (L-lysine, L-hydroxyproline). This shift indicated a metabolic priority change from structural synthesis to immune function maintenance.
• Regulation of Stemness: High-K⁺ stress caused a significant upregulation of TCF7 protein, correlating with dysfunctional stemness. MnO₂ intervention significantly downregulated this aberrant TCF7 expression. Flow cytometry and immunofluorescence showed that while High-K⁺ alone failed to generate functional stem-like cells, the combined K-MnO₂ treatment significantly increased the proportion of CD8⁺TCF-7⁺ cells (14.8% vs. 2.44% in the High-K⁺ group), restoring a functional stem-like phenotype.
• In Vivo Efficacy: In melanoma-bearing mice, MnO₂ intervention significantly prolonged survival compared to controls and High-K⁺ groups. The K-MnO₂ group showed improved survival over the High-K⁺ group, confirming that MnO₂ mitigates the immunosuppressive effects of high K⁺ in the TME.

Key Contributions

1. Ion-Regulation Strategy: The study proposes a novel tumor immunotherapy strategy based on regulating the extracellular ionic microenvironment (specifically K⁺) rather than solely targeting immune checkpoints or cytokines.
2. Mechanistic Insight: It elucidates the mechanism by which MnO₂ nanomaterials chelate extracellular K⁺, thereby alleviating metabolic stress, correcting amino acid deficiencies, and reversing the aberrant stem-like phenotype of CD8⁺ T cells driven by TCF7 overexpression.
3. Nanomaterial Application: It demonstrates the potential of $\alpha$-MnO₂ nanomaterials as a biocompatible carrier for tumor immunotherapy that effectively modulates the TME without obvious toxicity.

Significance and Claims
The authors claim that this study provides a theoretical basis and experimental support for a new pathway in tumor immunotherapy: "ionic microenvironment regulation-metabolic remodeling-T cell stemness activation." By chelating extracellular K⁺, MnO₂ nanomaterials can restore the metabolic state and anti-tumor function of stem-like CD8⁺ T cells, overcoming the limitations of traditional antibody-based therapies. The study suggests that MnO₂ is a promising agent for enhancing anti-tumor immunity by correcting the specific metabolic and epigenetic dysfunctions induced by the high-K⁺ tumor microenvironment. The authors acknowledge limitations, including the need for further elucidation of downstream signaling pathways (e.g., calcium signaling, mTOR) and validation across additional tumor models, but assert that their findings open a new path for cancer treatment strategies.